(Q43152152)

14 November 2017

Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren (English)

1 reference

14 November 2017

1 reference

2

1 reference

14 November 2017

3

1 reference

14 November 2017

Tuija Tapaninen

1

0 references

publication date

24 February 2010

1 reference

European Journal of Clinical Pharmacology

14 November 2017

1 reference

14 November 2017

66

1 reference

14 November 2017

497-502

1 reference

14 November 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1007/s00228-010-0796-3

14 November 2017

0 references

cites work

Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00228-010-0796-3

Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension

21 January 2018

1 reference

12 December 2020

Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes

1 reference

12 December 2020

Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily

1 reference

12 December 2020

Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren

1 reference

12 December 2020

Cyclosporine markedly raises the plasma concentrations of repaglinide

1 reference

12 December 2020

Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance

1 reference

12 December 2020

Absorption, Distribution, Metabolism, and Elimination of the Direct Renin Inhibitor Aliskiren in Healthy Volunteers

1 reference

12 December 2020

Renin inhibition with aliskiren: where are we now, and where are we going?

1 reference

12 December 2020

Interaction of common azole antifungals with P glycoprotein

1 reference

12 December 2020

Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects

1 reference

12 December 2020

Pharmacokinetic interactions with rifampicin : clinical relevance

1 reference

12 December 2020

Functional interaction of intestinal CYP3A4 and P-glycoprotein

1 reference

12 December 2020

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin

1 reference

12 December 2020

The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.

1 reference

12 December 2020

Clinical pharmacokinetics and pharmacodynamics of aliskiren

1 reference

12 December 2020

Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals

1 reference

12 December 2020

The preparation, purification, and amino acid sequence of a polypeptide renin substrate

1 reference

12 December 2020

Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein

1 reference

12 December 2020

Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.

1 reference

12 December 2020

Importance of P-glycoprotein at blood-tissue barriers

1 reference

12 December 2020

Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.

1 reference

12 December 2020

Rifampin drastically reduces plasma concentrations and effects of oral midazolam.

1 reference

12 December 2020

Structure-based design of aliskiren, a novel orally effective renin inhibitor

1 reference

12 December 2020

10.1007/S00228-010-0796-3

Identifiers

DOI

1 reference

14 November 2017

1 reference

PubMed ID

20179914